Anavex Life Sciences Corp. (AVXL) shares surged 5.61% in pre-market trading on Thursday, after H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on the stock and raised the price target from $40 to $42, citing the company's strong financial position and prospects for European approval of its lead drug candidate.
According to Selvaraju, Anavex's robust cash position and potential European approval for its Alzheimer's drug candidate, blarcamesine, drove the positive outlook and higher price target. The analyst expects the company's cash runway to extend well into 2025, supporting its development efforts.
Selvaraju highlighted blarcamesine's promising clinical data and regulatory pathway, anticipating potential approval in Europe next year. The drug candidate is currently under review by the European Medicines Agency (EMA) for the treatment of Alzheimer's disease.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。